]>
IRCT20210623051676N1 IRCT 2022-02-04 Mashhad University of Medical Sciences hypofractionated radiotherapy in esophageal carcinoma Determination of the pathological response of localized or locally advanced esophageal carcinoma to induction chemotherapy and concurrent chemotherapy with hypofractionated radiotherapy before surgery. 2021-10-28 anticipated 43 Complete https://irct.ir/trial/59930 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 esophageal cancer. Intervention group: Received 3 to 5 courses of weekly induction chemotherapy with paclitaxel (50 mg / m2) and carboplatin (AUC 2) followed by hypofractionated radiotherapy with a total dose of 40 Gy and 2.5 Gy per fraction. Yes - There is a plan to make this available What will be shared: all of data after making persons undetectable When: after publishing the outcomes To whom: Researchers working in academic and scientific institutions Conditions: For research, treatment and educational purposes Where to obtain: Refer to Shervin Mashreghi Moghaddam via email address or whatsapp number: emp_shervin@yahoo.com 00989358663171 How to obtain: Within a week Comments:
public Shervin Mashreghi Moghaddam
Omid hospital., Koohsangi Blvd
Mashhad Iran (Islamic Republic of) 9875674442 +98 51 3843 9335 emp_shervin@yahoo.com Mashhad University of Medical Sciences scientific Shervin Mashreghi Moghaddam
Omid hospital., Koohsangi Blvd
Mashhad Iran (Islamic Republic of) 9875674442 +98 51 3843 9335 emp_shervin@yahoo.com Mashhad University of Medical Sciences Iran (Islamic Republic of) carcinoma in thoracic or abdominal esophagus performance status above or equal to 70% in karnofsky criteria or less or equal to 1 in ECOG criteria presence of 3rd grade or more dysphasia or disease in T2-T4 N0 M0 or any T N+ M0 stage consent to the whole treatment program including surgery no limit no limit Both presence of metastatic disease presence of cervical esophagus invasion to heart, trachea, bronchus or aorta dissent to surgery history of cancer or other diseases that interfere to complete the treatment program C15.9 Malignant neoplasm of esophagus, unspecified Treatment - Other Intervention group: Received 3 to 5 courses of weekly induction chemotherapy with paclitaxel (50 mg / m2) and carboplatin (AUC 2) followed by hypofractionated radiotherapy with a total dose of 40 Gy and 2.5 Gy per fraction Percentage of pathological response based on tumor necrosis in microscopic examination. Timepoint: 4 weeks after completion of neoadjuvant chemoradiotherapy. Method of measurement: Pathological evaluation. Scale of dysphagia. Timepoint: before the intervention and after completing treatment. Method of measurement: dysphagia severity scale. Mashhad University of Medical Sciences Approved 2021-10-27 Ethics committee of Mashhad University of Medical Sciences omid hospital, koohsangi Avn. Mashhad Razavi Khorasan Iran (Islamic Republic of)